Last reviewed · How we verify

NCT05536466: LABRADOR

The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine

Status unknown NA Last updated 10 September 2022
What this trial tests

NA trial testing bariatric surgery in HIV Infections in 8 participants. Status unknown.

Timeline
30 September 2022
Primary endpoint
23 July 2023
1 August 2023

Quick facts

Lead sponsorRadboud University Medical Center
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment8
Start date30 September 2022
Primary completion23 July 2023
Estimated completion1 August 2023

Drugs / interventions tested

Conditions studied

Sponsor

Radboud University Medical Center

Who can join

18 and older, any sex, with HIV Infections or Bariatric Surgery Candidate. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

a multicentre phase IV study to collect evidence that a doravirine-based regimen can be safely and effectively administered to virologically suppressed HIV-infected patients undergoing bariatric suregery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of bariatric surgery

Trials testing the same drug.

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

Other Radboud University Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05536466.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing